董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barry J. Simon | 男 | President, Chief Administrative Officer and Director | 52 | 42.03万美元 | 未持股 | 2017-04-17 |
| Richard Kusserow | 男 | Director | 76 | 6.00万美元 | 未持股 | 2017-04-17 |
| John T. Potts | 男 | Director | 85 | 6.00万美元 | 未持股 | 2017-04-17 |
| Michael Blaszyk | 男 | Director | 64 | 39.35万美元 | 未持股 | 2017-04-17 |
| Patrick Soon Shiong | 男 | Chairman of the Board of Directors and Chief Executive Officer | 64 | 60.23万美元 | 未持股 | 2017-04-17 |
| John C. Thomas, Jr. | 男 | Director | 63 | 6.00万美元 | 未持股 | 2017-04-17 |
| Steve Gorlin | 男 | Vice Chairman of the Board of Directors | 79 | 18.60万美元 | 未持股 | 2017-04-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barry J. Simon | 男 | President, Chief Administrative Officer and Director | 52 | 42.03万美元 | 未持股 | 2017-04-17 |
| Richard J. Tajak | 男 | Chief Financial Officer | 64 | 未披露 | 未持股 | 2017-04-17 |
| Sonja Nelson | 女 | Chief Accounting Officer | 44 | 49.64万美元 | 未持股 | 2017-04-17 |
| Patrick Soon Shiong | 男 | Chairman of the Board of Directors and Chief Executive Officer | 64 | 60.23万美元 | 未持股 | 2017-04-17 |
董事简历
中英对照 | 中文 | 英文- Barry J. Simon
-
Barry J. Simon，2015年3月起，担任本公司的总裁、首席运营官、董事。2007年至2015年3月，他担任本公司的总裁、首席执行官、董事。加入本公司之前，他在多个公司担任过各种高管及咨询职务，包括：Roche Labs, F. Hoffmann-La Roche， 全球性的医疗保健公司；Connetics Corp.， 专业药品公司；Immunomedics, Inc.， 生物药品公司；Immusol, Inc.， 生物药品公司；HealthPro BioVentures, LLC， 医疗保健与生命科学投资银行；NorthSound Capital, LLC， 对冲基金。他曾就读于London School of Business、the Amos Tuck School of Business at Dartmouth College的企业培训课程；曾受过感染性疾病、麻醉、内科的临床训练，在纽约的SUNY Downstate, Health Sciences Center 获得医学博士学位。
Barry J. Simon has served as a member of our board of directors since 2007 and as our President and Chief Administrative Officer since January 2017 and Chief Operating Officer from March 2015 to December 2016. From 2007 to March 2015 Dr. Simon was also our President and Chief Executive Officer. Prior to joining us, he held various senior management and advisory positions at Roche Labs, Inc., a U.S. pharmaceutical company; F. Hoffmann-La Roche, Ltd., a global healthcare company; Connetics Corp., a specialty pharmaceutical company; Immunomedics, Inc., a biopharmaceutical company; Immusol, Inc., a biopharmaceutical company; HealthPro BioVentures, LLC, a healthcare and life sciences investment bank; and NorthSound Capital, LLC, a U.S.-based hedge fund. Dr. Simon has attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He is clinically trained in infectious diseases, anesthesiology, and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York. - Barry J. Simon，2015年3月起，担任本公司的总裁、首席运营官、董事。2007年至2015年3月，他担任本公司的总裁、首席执行官、董事。加入本公司之前，他在多个公司担任过各种高管及咨询职务，包括：Roche Labs, F. Hoffmann-La Roche， 全球性的医疗保健公司；Connetics Corp.， 专业药品公司；Immunomedics, Inc.， 生物药品公司；Immusol, Inc.， 生物药品公司；HealthPro BioVentures, LLC， 医疗保健与生命科学投资银行；NorthSound Capital, LLC， 对冲基金。他曾就读于London School of Business、the Amos Tuck School of Business at Dartmouth College的企业培训课程；曾受过感染性疾病、麻醉、内科的临床训练，在纽约的SUNY Downstate, Health Sciences Center 获得医学博士学位。
- Barry J. Simon has served as a member of our board of directors since 2007 and as our President and Chief Administrative Officer since January 2017 and Chief Operating Officer from March 2015 to December 2016. From 2007 to March 2015 Dr. Simon was also our President and Chief Executive Officer. Prior to joining us, he held various senior management and advisory positions at Roche Labs, Inc., a U.S. pharmaceutical company; F. Hoffmann-La Roche, Ltd., a global healthcare company; Connetics Corp., a specialty pharmaceutical company; Immunomedics, Inc., a biopharmaceutical company; Immusol, Inc., a biopharmaceutical company; HealthPro BioVentures, LLC, a healthcare and life sciences investment bank; and NorthSound Capital, LLC, a U.S.-based hedge fund. Dr. Simon has attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He is clinically trained in infectious diseases, anesthesiology, and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.
- Richard Kusserow
-
Richard Kusserow，2014年4月起，担任本公司董事。1997年至今，他一直担任Strategic Management Systems, Inc的总裁、首席执行官，该公司从事有效合规项目运营的开发、实施、衡量；1992年至今，担任Strategic Management Systems and Integrity Management Services的首席执行官，该公司为联邦政府提供一系列的服务，包括审计与调查、统计分析与数据分析。他曾创办Fraud Control Information Systems，并在1993-1997年间，担任总裁，这是制裁筛查服务公司；曾创办National Hotline Services Inc，并在1993-2005年间，担任总裁、执行顾问，这是电话道德热线服务提供商。作为全国合规项目方面的著名专家，他在1981-1992年间，担任U.S. Department of Health and Human Services的总检查长。他擅长于变化监管环境下的战略规划、解决问题、决策支持。他曾是Attorney General's Economic Crime Council的成员，曾被布什总统任命为National Advisory Commission on Law Enforcement的成员。担任总检察长之前，他是FBI的特工/主管，协调并监督芝加哥地区的7个有组织犯罪计划的相关团队，还曾是项目欺诈与腐败调查的专家。
Richard Kusserow has served as a member of our board of directors since April 2014. During 2010 to 2013 he served on the Audit and Corporate Responsibility Committee of the Catholic Health Partners Board. He is the President and Chief Executive Officer of Strategic Management Services, LLC., a firm specializing in the development, implementation and measurement of effective compliance program operations, a position he has held since 1997 and was, from 1992 through 2016 the Chief Executive Officer of Strategic Management Systems and Integrity Management Services, a firm that provides a variety of services to the federal government, including audits, investigations, statistical analysis, and data analysis. Mr. Kusserow founded and served as the President of the Fraud Control Information Systems, a provider of sanction screening services, from 1993 to 1997 and founded and served as President and Chief Executive Officer of the National Hotline Services Inc., a phone-based ethics hotline services provider, from 1993 to 2005. One of the leading experts in the country on compliance programs, Mr. Kusserow served as the Inspector General of the U.S. Department of Health and Human Services from 1981 to 1992 responsible for all audits and investigations related to the $650 billion outlays of the Department. Mr. Kusserow specializes in strategic planning, problem solving and the support of decision making in the changing regulatory environment. Mr. Kusserow was a Member of the Attorney General’s Economic Crime Council and was appointed by President George H. W. Bush as a Commissioner of the National Advisory Commission on Law Enforcement. Before his appointment to Inspector General, Mr. Kusserow was a Special Agent/Supervisor for the FBI, where he coordinated and supervised the seven squads constituting the Organized Crime Program in Chicago and served as a specialist in program fraud and corruption investigations. - Richard Kusserow，2014年4月起，担任本公司董事。1997年至今，他一直担任Strategic Management Systems, Inc的总裁、首席执行官，该公司从事有效合规项目运营的开发、实施、衡量；1992年至今，担任Strategic Management Systems and Integrity Management Services的首席执行官，该公司为联邦政府提供一系列的服务，包括审计与调查、统计分析与数据分析。他曾创办Fraud Control Information Systems，并在1993-1997年间，担任总裁，这是制裁筛查服务公司；曾创办National Hotline Services Inc，并在1993-2005年间，担任总裁、执行顾问，这是电话道德热线服务提供商。作为全国合规项目方面的著名专家，他在1981-1992年间，担任U.S. Department of Health and Human Services的总检查长。他擅长于变化监管环境下的战略规划、解决问题、决策支持。他曾是Attorney General's Economic Crime Council的成员，曾被布什总统任命为National Advisory Commission on Law Enforcement的成员。担任总检察长之前，他是FBI的特工/主管，协调并监督芝加哥地区的7个有组织犯罪计划的相关团队，还曾是项目欺诈与腐败调查的专家。
- Richard Kusserow has served as a member of our board of directors since April 2014. During 2010 to 2013 he served on the Audit and Corporate Responsibility Committee of the Catholic Health Partners Board. He is the President and Chief Executive Officer of Strategic Management Services, LLC., a firm specializing in the development, implementation and measurement of effective compliance program operations, a position he has held since 1997 and was, from 1992 through 2016 the Chief Executive Officer of Strategic Management Systems and Integrity Management Services, a firm that provides a variety of services to the federal government, including audits, investigations, statistical analysis, and data analysis. Mr. Kusserow founded and served as the President of the Fraud Control Information Systems, a provider of sanction screening services, from 1993 to 1997 and founded and served as President and Chief Executive Officer of the National Hotline Services Inc., a phone-based ethics hotline services provider, from 1993 to 2005. One of the leading experts in the country on compliance programs, Mr. Kusserow served as the Inspector General of the U.S. Department of Health and Human Services from 1981 to 1992 responsible for all audits and investigations related to the $650 billion outlays of the Department. Mr. Kusserow specializes in strategic planning, problem solving and the support of decision making in the changing regulatory environment. Mr. Kusserow was a Member of the Attorney General’s Economic Crime Council and was appointed by President George H. W. Bush as a Commissioner of the National Advisory Commission on Law Enforcement. Before his appointment to Inspector General, Mr. Kusserow was a Special Agent/Supervisor for the FBI, where he coordinated and supervised the seven squads constituting the Organized Crime Program in Chicago and served as a specialist in program fraud and corruption investigations.
- John T. Potts
-
John T. Potts自2009年10月，就担任BioSante董事，当该公司和Cell Genesys, Inc.合并后，他被选举为董事。他在科学和医学方面有着四十多年的经历。 Potts博士目前是杰克逊市哈佛医学院的临床医学教授。在宾夕法尼亚大学的医学训练后，从1957年到1959年，他在Massachusetts General Hospital MGH（麻省综合医院） 实习并做住院医生，然后去了 National Institutes of Health （NIH）（美国国立卫生研究院） 和诺贝尔奖得主Christian Anfinsen一起工作，专研蛋白质化学。 1959年到1968年，Potts博士从MGH的内分泌科主任退休后，就留在NIH 工作。从1981年到1996年，他担任医学系主任、内科医师主任。 从1995年到2004年，在他担任研究主管期间，负责在MGH发展战略的保持和进行大量的科学研究工作的加强，这也是他坚持到目前的努力方向。作为500多本科学书籍的出版作者或联合作者，他也是 National Academy of Sciences（美国国家科学院）、医学研究院的成员、美国艺术和科学研究院的成员。 Potts博士是Zeltiq Aesthetics的董事， 是 Radius Health, Inc.的创立者， Radius Health, Inc.和MPM Capital科学顾问委员会的一员。在过去的五年中， Potts博士先在Cell Genesys, Inc和Celltaxsys担任董事。
John T. Potts has served as a member of our board of directors since April 2014. Dr. Potts serves as the Distinguished Jackson Professor of Clinical Medicine at the Massachusetts General Hospital, or MGH, and Harvard Medical School and on the MPM BioVentures Medical & Scientific Advisory Board. After medical training at the University of Pennsylvania, he completed his internship and residency at MGH from 1957 to 1959 and then went to the National Institutes of Health, or NIH, to work with Nobel Laureate Christian Anfinsen in protein chemistry. Dr. Potts remained at the NIH from 1959 to 1968 when he returned to MGH as Chief of the Endocrine Unit. He served as Chairman of the Department of Medicine and Physician-in-Chief from 1981 to 1996 and as Director of Research from 1995 to 2004. Dr. Potts has authored or co-authored over 500 scientific publications, is the recipient of the Fred Conrad Koch Award of the Endocrine Society and is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He holds active and honorary memberships in numerous scientific and professional organizations. - John T. Potts自2009年10月，就担任BioSante董事，当该公司和Cell Genesys, Inc.合并后，他被选举为董事。他在科学和医学方面有着四十多年的经历。 Potts博士目前是杰克逊市哈佛医学院的临床医学教授。在宾夕法尼亚大学的医学训练后，从1957年到1959年，他在Massachusetts General Hospital MGH（麻省综合医院） 实习并做住院医生，然后去了 National Institutes of Health （NIH）（美国国立卫生研究院） 和诺贝尔奖得主Christian Anfinsen一起工作，专研蛋白质化学。 1959年到1968年，Potts博士从MGH的内分泌科主任退休后，就留在NIH 工作。从1981年到1996年，他担任医学系主任、内科医师主任。 从1995年到2004年，在他担任研究主管期间，负责在MGH发展战略的保持和进行大量的科学研究工作的加强，这也是他坚持到目前的努力方向。作为500多本科学书籍的出版作者或联合作者，他也是 National Academy of Sciences（美国国家科学院）、医学研究院的成员、美国艺术和科学研究院的成员。 Potts博士是Zeltiq Aesthetics的董事， 是 Radius Health, Inc.的创立者， Radius Health, Inc.和MPM Capital科学顾问委员会的一员。在过去的五年中， Potts博士先在Cell Genesys, Inc和Celltaxsys担任董事。
- John T. Potts has served as a member of our board of directors since April 2014. Dr. Potts serves as the Distinguished Jackson Professor of Clinical Medicine at the Massachusetts General Hospital, or MGH, and Harvard Medical School and on the MPM BioVentures Medical & Scientific Advisory Board. After medical training at the University of Pennsylvania, he completed his internship and residency at MGH from 1957 to 1959 and then went to the National Institutes of Health, or NIH, to work with Nobel Laureate Christian Anfinsen in protein chemistry. Dr. Potts remained at the NIH from 1959 to 1968 when he returned to MGH as Chief of the Endocrine Unit. He served as Chairman of the Department of Medicine and Physician-in-Chief from 1981 to 1996 and as Director of Research from 1995 to 2004. Dr. Potts has authored or co-authored over 500 scientific publications, is the recipient of the Fred Conrad Koch Award of the Endocrine Society and is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He holds active and honorary memberships in numerous scientific and professional organizations.
- Michael Blaszyk
-
Michael Blaszyk，2015年7月以来，他曾一直担任我们董事会的成员。他曾一直担任Dignity Health公司（原为Catholic Healthcare West公司，非营利性公益公司）的首席财务官（2000年12月以来）。加入Dignity Health公司之前，他曾担任俄亥俄州克利夫兰大学医院的卫生系统（University Hospitals Health System，一个卫生保健系统）的高级副总裁兼首席财务官（从1997年10月到2000年12月）。他此前也曾担任Mercer公司（原为William M. Mercer公司，全球咨询公司）的东北地区卫生保健供应商咨询实践的管理合伙人，以及全球咨询公司（一个非盈利的学术医疗中心）的执行副总裁。他是Sound Physicians公司（一家费森尤斯公司）的董事和审计委员会成员。他持有Wayne State University的生命科学学士学位，以及科罗拉多大学（University of Colorado）的卫生服务管理硕士学位。
Michael Blaszyk has served as a member of our board of directors since July 2015. Mr. Blaszyk has served as the chief financial officer for Dignity Health formerly known as Catholic Healthcare West, a not-for-profit public benefit corporation, since December 2000. Prior to joining Dignity Health, Mr. Blaszyk was the senior vice president and chief financial officer for University Hospitals Health System in Cleveland, Ohio, a healthcare system, from October 1997 to December 2000. Mr. Blaszyk also previously served as the managing partner of the Northeast region Health Care Provider Consulting Practice for Merger LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president at Boston Medical Center, a non-profit academic medical center. Mr. Blaszyk is a director and member of the audit committee of Sound Physicians, Inc., a Fresenius company. He received his bachelor’s degree in life sciences from Wayne State University and his master’s degree in health services administration from the University of Colorado. - Michael Blaszyk，2015年7月以来，他曾一直担任我们董事会的成员。他曾一直担任Dignity Health公司（原为Catholic Healthcare West公司，非营利性公益公司）的首席财务官（2000年12月以来）。加入Dignity Health公司之前，他曾担任俄亥俄州克利夫兰大学医院的卫生系统（University Hospitals Health System，一个卫生保健系统）的高级副总裁兼首席财务官（从1997年10月到2000年12月）。他此前也曾担任Mercer公司（原为William M. Mercer公司，全球咨询公司）的东北地区卫生保健供应商咨询实践的管理合伙人，以及全球咨询公司（一个非盈利的学术医疗中心）的执行副总裁。他是Sound Physicians公司（一家费森尤斯公司）的董事和审计委员会成员。他持有Wayne State University的生命科学学士学位，以及科罗拉多大学（University of Colorado）的卫生服务管理硕士学位。
- Michael Blaszyk has served as a member of our board of directors since July 2015. Mr. Blaszyk has served as the chief financial officer for Dignity Health formerly known as Catholic Healthcare West, a not-for-profit public benefit corporation, since December 2000. Prior to joining Dignity Health, Mr. Blaszyk was the senior vice president and chief financial officer for University Hospitals Health System in Cleveland, Ohio, a healthcare system, from October 1997 to December 2000. Mr. Blaszyk also previously served as the managing partner of the Northeast region Health Care Provider Consulting Practice for Merger LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president at Boston Medical Center, a non-profit academic medical center. Mr. Blaszyk is a director and member of the audit committee of Sound Physicians, Inc., a Fresenius company. He received his bachelor’s degree in life sciences from Wayne State University and his master’s degree in health services administration from the University of Colorado.
- Patrick Soon Shiong
-
Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. - Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
- Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.
- John C. Thomas, Jr.
-
John C. Thomas, Jr.从2012年开始担任QLT的董事，并担任QLT的审计与风险、公司治理与提名和薪酬委员会的委员。Thomas先生拥有超过38年的多个财务与会计职位的工作经验，最后28年在医疗、制药与设备领域度过。Thomas先生目前还担任CorMatrix的首席财务官、秘书与董事（从2001年开始任职），这是一家私人所有的的医疗设备公司，并担任Motion Reality, Inc.的首席财务官、秘书与董事（从1991年开始任职），这是一家动作捕捉与模拟公司。过去10年间，Thomas先生担任DemeRx, Inc.的代理首席财务官（从2010年到2011年）；担任MRI干预公司（MRI Interventions, Inc.）的首席财务官（从1998年到2010年），担任MiMedx Group, Inc. 的首席财务官（从2007年到2008年），并担任DARA BioSciences的首席财务官（从2003年到2009年）；并担任MRI干预公司的董事（从2004年到2011年），于2012年担任DARA BioSciences的董事。在这之前，Thomas先生还担任沃克中学（Walker School）的理事，随后担任财务委员会主席， 这是一家私人的从学前班到12学级的小学（从1999年到2012年）。Thomas先生是一位注册会计师，并毕业于弗吉尼亚大学（University of Virginia）麦金太尔商学院（McIntire School of Commerce），于1975年以优异的成绩获得商业理学学士学位。
John C. Thomas, Jr. will be a director upon the completion of the Corporate Conversion. Since 2018 Mr. Thomas has served as the Chief Financial Officer and Secretary of SmartPharm Therapeutics, Inc, a genetic research and development company. In late 2017 Mr. Thomas rejoined DemeRx, Inc., a privately held company developing non-additive treatments for drug addiction, as the Chief Financial Officer after previously being the Chief Financial Officer from 2010 to 2013. Since April 2014 Mr. Thomas has served as a director of NantKwest, Inc. Nasdaq: NK and is chairperson of the audit committee and a member of the compensation committee. From 2001 until 2018 Mr. Thomas served as Chief Financial Officer and Secretary, and from 2001 to 2016 as a director of CorMatrix Cardiovascular, a privately held medical device company. He has also served as Chief Financial Officer, Secretary, and Director of Motion Reality, Inc., a motion capture and simulation company, since 1991. From 2012 until 2019 Mr. Thomas served as a director of Novelion Therapeutics, Inc. (formerly QLT, Inc.), a public company focused on rare diseases and was the Chairperson of their Audit and Risk Committee and Nominating and Governance Committee. During the past ten years, Mr. Thomas served as acting Chief Financial Officer for DemeRx, Inc., MRI Interventions, Inc., MiMedx Group, Inc., and DARA BioSciences and as a director of MRI Interventions, Inc. Between 1999 and 2012 Mr. Thomas served as a Trustee and subsequently the Chairman of the Finance Committee of The Walker School, a private school. Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntire School of Commerce. - John C. Thomas, Jr.从2012年开始担任QLT的董事，并担任QLT的审计与风险、公司治理与提名和薪酬委员会的委员。Thomas先生拥有超过38年的多个财务与会计职位的工作经验，最后28年在医疗、制药与设备领域度过。Thomas先生目前还担任CorMatrix的首席财务官、秘书与董事（从2001年开始任职），这是一家私人所有的的医疗设备公司，并担任Motion Reality, Inc.的首席财务官、秘书与董事（从1991年开始任职），这是一家动作捕捉与模拟公司。过去10年间，Thomas先生担任DemeRx, Inc.的代理首席财务官（从2010年到2011年）；担任MRI干预公司（MRI Interventions, Inc.）的首席财务官（从1998年到2010年），担任MiMedx Group, Inc. 的首席财务官（从2007年到2008年），并担任DARA BioSciences的首席财务官（从2003年到2009年）；并担任MRI干预公司的董事（从2004年到2011年），于2012年担任DARA BioSciences的董事。在这之前，Thomas先生还担任沃克中学（Walker School）的理事，随后担任财务委员会主席， 这是一家私人的从学前班到12学级的小学（从1999年到2012年）。Thomas先生是一位注册会计师，并毕业于弗吉尼亚大学（University of Virginia）麦金太尔商学院（McIntire School of Commerce），于1975年以优异的成绩获得商业理学学士学位。
- John C. Thomas, Jr. will be a director upon the completion of the Corporate Conversion. Since 2018 Mr. Thomas has served as the Chief Financial Officer and Secretary of SmartPharm Therapeutics, Inc, a genetic research and development company. In late 2017 Mr. Thomas rejoined DemeRx, Inc., a privately held company developing non-additive treatments for drug addiction, as the Chief Financial Officer after previously being the Chief Financial Officer from 2010 to 2013. Since April 2014 Mr. Thomas has served as a director of NantKwest, Inc. Nasdaq: NK and is chairperson of the audit committee and a member of the compensation committee. From 2001 until 2018 Mr. Thomas served as Chief Financial Officer and Secretary, and from 2001 to 2016 as a director of CorMatrix Cardiovascular, a privately held medical device company. He has also served as Chief Financial Officer, Secretary, and Director of Motion Reality, Inc., a motion capture and simulation company, since 1991. From 2012 until 2019 Mr. Thomas served as a director of Novelion Therapeutics, Inc. (formerly QLT, Inc.), a public company focused on rare diseases and was the Chairperson of their Audit and Risk Committee and Nominating and Governance Committee. During the past ten years, Mr. Thomas served as acting Chief Financial Officer for DemeRx, Inc., MRI Interventions, Inc., MiMedx Group, Inc., and DARA BioSciences and as a director of MRI Interventions, Inc. Between 1999 and 2012 Mr. Thomas served as a Trustee and subsequently the Chairman of the Finance Committee of The Walker School, a private school. Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia, McIntire School of Commerce.
- Steve Gorlin
-
Steve Gorlin是Debride Inc.的联合创始人，其为第一家被Medovex收购的公司。过去40年里，Gorlin先生创立了几家生物技术与制药公司，包括HycorBiomedical, Inc.，被安捷伦科技公司（Agilent）收购，Theragenics Corporation（纽交所代码：TGX），CytRx Corporation（纳斯达克代码：CYTR），Medicis Pharmaceutical Corporation（以大约26亿美元被出售给Valeant ）， EntreMed, Inc.（纳斯达克代码：ENMD），MRI Interventions（MRIC）， DARA BioSciences, Inc.（纳斯达克代码：DARA），MiMedx（纳斯达克代码： MDXG），与Medivation, Inc.（纳斯达克代码：MDVN）。Gorlin先生担任约翰霍普金斯医学院（Johns Hopkins School of Medicine）的商业顾问委员会委员多年，并担任约翰霍普金斯大学生物医学工程咨询委员会（Johns Hopkins BioMedical Engineering Advisory Board）委员。他目前担任安德鲁斯研究所（Andrews Institute）的董事。Gorlin先生创立了多个非医疗相关的公司，包括Perma-Fix, Inc.、Pretty Good Privacy, Inc.（被出售给美国网络联盟公司（Network Associates） ），和NTC China。他创立了The Touch Foundation，这是一家盲人非赢利机构，并是糖尿病儿童机构Camp Kudzu创立的主要财务出资人。目前，他担任DemeRx, Inc.、Conkwest, Inc.的执行委员会委员和董事会董事，并担任NTC China, Inc.的董事。
Steve Gorlin,has served as the Company's director since June 2020. He has founded many biopharma companies including Hycor Biomedical, Theragenics, Medicis Pharmaceutical, EntreMed, MRI Interventions, DARA BioSciences, MiMedx, Medivation (sold to Pfizer for $14 billion) and NantKwest. Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board. He is currently a member of the Research Institute Advisory Committee (RIAC) of Massachusetts General Hospital. He started The Touch Foundation, a nonprofit organization for the blind, and was a principal contributor to Camp Kudzu for diabetic children. - Steve Gorlin是Debride Inc.的联合创始人，其为第一家被Medovex收购的公司。过去40年里，Gorlin先生创立了几家生物技术与制药公司，包括HycorBiomedical, Inc.，被安捷伦科技公司（Agilent）收购，Theragenics Corporation（纽交所代码：TGX），CytRx Corporation（纳斯达克代码：CYTR），Medicis Pharmaceutical Corporation（以大约26亿美元被出售给Valeant ）， EntreMed, Inc.（纳斯达克代码：ENMD），MRI Interventions（MRIC）， DARA BioSciences, Inc.（纳斯达克代码：DARA），MiMedx（纳斯达克代码： MDXG），与Medivation, Inc.（纳斯达克代码：MDVN）。Gorlin先生担任约翰霍普金斯医学院（Johns Hopkins School of Medicine）的商业顾问委员会委员多年，并担任约翰霍普金斯大学生物医学工程咨询委员会（Johns Hopkins BioMedical Engineering Advisory Board）委员。他目前担任安德鲁斯研究所（Andrews Institute）的董事。Gorlin先生创立了多个非医疗相关的公司，包括Perma-Fix, Inc.、Pretty Good Privacy, Inc.（被出售给美国网络联盟公司（Network Associates） ），和NTC China。他创立了The Touch Foundation，这是一家盲人非赢利机构，并是糖尿病儿童机构Camp Kudzu创立的主要财务出资人。目前，他担任DemeRx, Inc.、Conkwest, Inc.的执行委员会委员和董事会董事，并担任NTC China, Inc.的董事。
- Steve Gorlin,has served as the Company's director since June 2020. He has founded many biopharma companies including Hycor Biomedical, Theragenics, Medicis Pharmaceutical, EntreMed, MRI Interventions, DARA BioSciences, MiMedx, Medivation (sold to Pfizer for $14 billion) and NantKwest. Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board. He is currently a member of the Research Institute Advisory Committee (RIAC) of Massachusetts General Hospital. He started The Touch Foundation, a nonprofit organization for the blind, and was a principal contributor to Camp Kudzu for diabetic children.
高管简历
中英对照 | 中文 | 英文- Barry J. Simon
Barry J. Simon，2015年3月起，担任本公司的总裁、首席运营官、董事。2007年至2015年3月，他担任本公司的总裁、首席执行官、董事。加入本公司之前，他在多个公司担任过各种高管及咨询职务，包括：Roche Labs, F. Hoffmann-La Roche， 全球性的医疗保健公司；Connetics Corp.， 专业药品公司；Immunomedics, Inc.， 生物药品公司；Immusol, Inc.， 生物药品公司；HealthPro BioVentures, LLC， 医疗保健与生命科学投资银行；NorthSound Capital, LLC， 对冲基金。他曾就读于London School of Business、the Amos Tuck School of Business at Dartmouth College的企业培训课程；曾受过感染性疾病、麻醉、内科的临床训练，在纽约的SUNY Downstate, Health Sciences Center 获得医学博士学位。
Barry J. Simon has served as a member of our board of directors since 2007 and as our President and Chief Administrative Officer since January 2017 and Chief Operating Officer from March 2015 to December 2016. From 2007 to March 2015 Dr. Simon was also our President and Chief Executive Officer. Prior to joining us, he held various senior management and advisory positions at Roche Labs, Inc., a U.S. pharmaceutical company; F. Hoffmann-La Roche, Ltd., a global healthcare company; Connetics Corp., a specialty pharmaceutical company; Immunomedics, Inc., a biopharmaceutical company; Immusol, Inc., a biopharmaceutical company; HealthPro BioVentures, LLC, a healthcare and life sciences investment bank; and NorthSound Capital, LLC, a U.S.-based hedge fund. Dr. Simon has attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He is clinically trained in infectious diseases, anesthesiology, and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.- Barry J. Simon，2015年3月起，担任本公司的总裁、首席运营官、董事。2007年至2015年3月，他担任本公司的总裁、首席执行官、董事。加入本公司之前，他在多个公司担任过各种高管及咨询职务，包括：Roche Labs, F. Hoffmann-La Roche， 全球性的医疗保健公司；Connetics Corp.， 专业药品公司；Immunomedics, Inc.， 生物药品公司；Immusol, Inc.， 生物药品公司；HealthPro BioVentures, LLC， 医疗保健与生命科学投资银行；NorthSound Capital, LLC， 对冲基金。他曾就读于London School of Business、the Amos Tuck School of Business at Dartmouth College的企业培训课程；曾受过感染性疾病、麻醉、内科的临床训练，在纽约的SUNY Downstate, Health Sciences Center 获得医学博士学位。
- Barry J. Simon has served as a member of our board of directors since 2007 and as our President and Chief Administrative Officer since January 2017 and Chief Operating Officer from March 2015 to December 2016. From 2007 to March 2015 Dr. Simon was also our President and Chief Executive Officer. Prior to joining us, he held various senior management and advisory positions at Roche Labs, Inc., a U.S. pharmaceutical company; F. Hoffmann-La Roche, Ltd., a global healthcare company; Connetics Corp., a specialty pharmaceutical company; Immunomedics, Inc., a biopharmaceutical company; Immusol, Inc., a biopharmaceutical company; HealthPro BioVentures, LLC, a healthcare and life sciences investment bank; and NorthSound Capital, LLC, a U.S.-based hedge fund. Dr. Simon has attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He is clinically trained in infectious diseases, anesthesiology, and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.
- Richard J. Tajak
RichardJ.Tajak自2016年1月起担任我们的首席财务官。Tajak先生自2014年1月起担任NantPharma，LLC（一家专业制药公司，Nantworks，LLC的全资子公司）的首席财务官，自2014年6月起担任首席运营官。在此之前，2011年7月至2013年12月，Tajak先生担任Nantworks，LLC的首席财务官。在加入Nantworks，LLC之前，Tajak先生于2008年4月至2011年6月担任App Pharmaceuticals，Inc.（一家价值10亿美元的仿制药公司）的执行Vice President兼首席财务官，此前他于2008年3月加入该公司担任高级副总裁，Finance。在此之前，他高级副总裁，Astellas Pharmaceuticals，Inc.北美部门的15亿美元财务。他早期的职业生涯任职于Fujisawa梦百合/USA和Lyphomed，Inc.，在那里他在会计、金融、SEC报告、审计、税务和公司运营领域的责任水平不断提高。Tajak先生拥有圣母大学（University of Notre Dame）金融学学士学位和工商管理硕士学位，是一名注册会计师。
Richard J. Tajak has served as our Chief Financial Officer since January 2016. Mr. Tajak has served as Chief Financial Officer of NantPharma, LLC, a specialty pharmaceutical company and wholly-owned subsidiary of NantWorks, LLC, since January 2014 and as Chief Operating Officer since June 2014. Prior to that, from July 2011 to December 2013 Mr. Tajak served as Chief Financial Officer of NantWorks, LLC. Prior to NantWorks, LLC, Mr. Tajak served as Executive Vice President and Chief Financial Officer of APP Pharmaceuticals, Inc., a $1 billion generic pharmaceutical company, from April 2008 to June 2011 after having joined the company as Senior Vice President, Finance in March 2008. Prior to that, he was Senior Vice President, Finance for the $1.5 billion North American division of Astellas Pharmaceuticals, Inc. His earlier career was at Fujisawa Healthcare/USA and Lyphomed, Inc., where he had increasing levels of responsibility in the areas of accounting, finance, SEC reporting, audit, tax, and corporate operations. Mr. Tajak holds a Bachelors degree in Finance and a Masters of Business Administration from the University of Notre Dame, and is a Certified Public Accountant.- RichardJ.Tajak自2016年1月起担任我们的首席财务官。Tajak先生自2014年1月起担任NantPharma，LLC（一家专业制药公司，Nantworks，LLC的全资子公司）的首席财务官，自2014年6月起担任首席运营官。在此之前，2011年7月至2013年12月，Tajak先生担任Nantworks，LLC的首席财务官。在加入Nantworks，LLC之前，Tajak先生于2008年4月至2011年6月担任App Pharmaceuticals，Inc.（一家价值10亿美元的仿制药公司）的执行Vice President兼首席财务官，此前他于2008年3月加入该公司担任高级副总裁，Finance。在此之前，他高级副总裁，Astellas Pharmaceuticals，Inc.北美部门的15亿美元财务。他早期的职业生涯任职于Fujisawa梦百合/USA和Lyphomed，Inc.，在那里他在会计、金融、SEC报告、审计、税务和公司运营领域的责任水平不断提高。Tajak先生拥有圣母大学（University of Notre Dame）金融学学士学位和工商管理硕士学位，是一名注册会计师。
- Richard J. Tajak has served as our Chief Financial Officer since January 2016. Mr. Tajak has served as Chief Financial Officer of NantPharma, LLC, a specialty pharmaceutical company and wholly-owned subsidiary of NantWorks, LLC, since January 2014 and as Chief Operating Officer since June 2014. Prior to that, from July 2011 to December 2013 Mr. Tajak served as Chief Financial Officer of NantWorks, LLC. Prior to NantWorks, LLC, Mr. Tajak served as Executive Vice President and Chief Financial Officer of APP Pharmaceuticals, Inc., a $1 billion generic pharmaceutical company, from April 2008 to June 2011 after having joined the company as Senior Vice President, Finance in March 2008. Prior to that, he was Senior Vice President, Finance for the $1.5 billion North American division of Astellas Pharmaceuticals, Inc. His earlier career was at Fujisawa Healthcare/USA and Lyphomed, Inc., where he had increasing levels of responsibility in the areas of accounting, finance, SEC reporting, audit, tax, and corporate operations. Mr. Tajak holds a Bachelors degree in Finance and a Masters of Business Administration from the University of Notre Dame, and is a Certified Public Accountant.
- Sonja Nelson
Sonja Nelson于2016年5月被任命为我们的首席会计官，并自2015年11月起担任我们的副总裁兼公司财务总监。在加入该公司之前，纳尔逊女士曾担任分子诊断公司Altheadx，Inc.的Vice President兼公司财务总监，并于2014年7月至2015年10月受聘为该公司IPO做准备。此前，纳尔逊女士曾于2012年5月至2014年6月担任CadencePharmaceuticals，Inc.的高级董事兼财务总监。在此之前，Nelson从2008年9月到2012年5月担任Cricket Communications，Inc.（一家价值30亿美元的无线服务提供商）总会计主管。Nelson女士在毕马威会计师事务所（KPMG LLP）开始她的职业生涯，持有德国普福尔茨海姆应用科学大学（University of Applied Sciences）会计和税收学士学位，是一名注册会计师。
Sonja Nelson,has served on Motus Gi Holdings, Inc. Board since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NASDAQ: AMAM). Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor's degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant.- Sonja Nelson于2016年5月被任命为我们的首席会计官，并自2015年11月起担任我们的副总裁兼公司财务总监。在加入该公司之前，纳尔逊女士曾担任分子诊断公司Altheadx，Inc.的Vice President兼公司财务总监，并于2014年7月至2015年10月受聘为该公司IPO做准备。此前，纳尔逊女士曾于2012年5月至2014年6月担任CadencePharmaceuticals，Inc.的高级董事兼财务总监。在此之前，Nelson从2008年9月到2012年5月担任Cricket Communications，Inc.（一家价值30亿美元的无线服务提供商）总会计主管。Nelson女士在毕马威会计师事务所（KPMG LLP）开始她的职业生涯，持有德国普福尔茨海姆应用科学大学（University of Applied Sciences）会计和税收学士学位，是一名注册会计师。
- Sonja Nelson,has served on Motus Gi Holdings, Inc. Board since June 2021. In June 2021, Ms. Nelson began serving as the Chief Financial Officer of Ambrx Biopharma, Inc, (NASDAQ: AMAM). Prior to that, Ms. Nelson, served as the Senior Vice President, Finance, of ImmunityBio, Inc. (NASDAQ: IBRX), from March 2021 to June 2021. Ms. Nelson served as the Chief Financial Officer of NantKwest, Inc. from June 2018 to March 2021, at which time NantKwest, Inc. merged with ImmunityBio, Inc. (NASDAQ: IBRX). Ms. Nelson previously served as the Chief Accounting Officer of NantKwest, Inc. from May 2016 to June 2018 and as the VP/Corporate Controller of NantKwest, Inc. from November 2015 to May 2016. Ms. Nelson also served as a director of Inex Bio (a subsidiary of NantKwest, Inc., now merged with ImmunityBio, Inc. (NASDAQ: IBRX)) from October 2017 to June 2021. Prior to joining NantKwest, Inc., Ms. Nelson was Vice President and Corporate Controller at AltheaDx, Inc. from July 2014 through October 2015. Previously, Ms. Nelson was Senior Director and Controller at Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc) from May 2012 through June 2014. Prior to that, Ms. Nelson was Director, General Accounting at Cricket Communications, Inc. (acquired by AT&T, Inc.) from September 2008 through May 2012. Ms. Nelson began her career with KPMG LLP, holds a Bachelor's degree in business administration with specialization in taxation and auditing from the University of Applied Sciences in Pforzheim, Germany, and is a Certified Public Accountant.
- Patrick Soon Shiong
Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.- Patrick Soon Shiong于2015年3月被任命为我们的董事会主席兼首席执行官。Soon Shiong博士此前曾于2014年12月至2015年3月担任我们的董事会联席主席，并于2015年1月至2015年3月担任我们的首席医疗官。他于2011年创立Nantworks公司（公司的生态系统，为基因和医疗信息的安全共享创建一个变革性的全球健康信息和下一代药物开发网络）。Soon Shiong博士是一位医生，外科医生和科学家，他开创了糖尿病和癌症的新型疗法，发表了100多篇科学论文，并就跨越众多领域的突破性进展发布了230多项专利。Soon Shiong博士为糖尿病患者进行了世界上第一例封装的人类胰岛移植，第一例工程化胰岛细胞移植以及第一例猪对人胰岛细胞移植。他发明并开发了Abraxane，这是美国FDA批准的第一个用于治疗癌症的蛋白纳米颗粒白蛋白结合输送技术。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon Shiong博士担任两家全球制药公司的创始人，董事长兼首席执行官，美国制药合作伙伴于2008年以46亿美元的价格出售给Fresenius SE，Abraxis Bioscience（于2010年以38亿美元的价格出售给新基医药公司）。Soon Shiong博士担任Chan Soon Shiong Family Foundation的主席和Chan Soon Siong分子医学研究所的主席兼首席执行官，这是一家非营利医疗研究机构。他目前担任两党政策中心（the Bipartisan Policy Center）的首席执行官健康与创新委员会的联席主席，也是美国银行（Bank of America）的全球顾问委员会的成员。他是加州大学洛杉矶分校（UCLA）的外科兼职教授、伦敦帝国理工学院（Imperial College of London）的客座教授、加州大学洛杉矶分校无线健康研究所（UCLA Wireless Health Institute）的执行董事、加州远程健康网络（California TeleHealth Network）的董事会成员，以及普罗维登斯健康公司（Providence Health）的癌症服务和生物信息学全球董事。美国国家医学图书馆的朋友们为他颁发了杰出医学奖。Soon Shiong博士拥有the University of the Witwatersrand的医学学位和M.SC.British Columbia大学的科学博士学位。
- Patrick Soon Shiong was appointed Chairman of our board of directors and Chief Executive Officer in March 2015. Dr. Soon Shiong previously served as our Co-Chairman of our board of directors from December 2014 to March 2015 and as our Chief Medical Officer from January 2015 to March 2015. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 230 issued patents on groundbreaking advancements spanning a myriad of fields. Dr. Soon Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant, and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005 lung cancer in 2012 and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010 Dr. Soon Shiong served as founder, Chairman, and CEO of two global pharmaceutical companies, American Pharmaceutical Partners sold to Fresenius SE for $4.6 billion in 2008 and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). Dr. Soon Shiong serves as Chairman of the Chan Soon Shiong Family Foundation and Chairman and CEO of the Chan Soon Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Soon Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.